secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001171843-24-006056
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q3 net loss $42.1M; barzolvolimab meets Phase 2 CIndU endpoints
-----------------------------------------------------------------------

- Net loss of $42.1M ($0.64 per share) vs $38.3M in Q3 2023; revenue $3.2M vs $1.5M.
- Cash $756.0M as of Sep 30, 2024, down from $802.3M; expects to fund operations through 2027.
- Barzolvolimab met all primary/secondary endpoints in Phase 2 CIndU; up to 57.6% complete response in SD.
- Global Phase 3 CSU trials (EMBARQ-CSU1/2) actively enrolling; CIndU Phase 3 planned for 2025.
- First bispecific CDX-622 (SCF/TSLP) entering Phase 1 in Q4 2024; CDX-585 development halted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184324006056/0001171843-24-006056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184324006056/f8k_110624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer